We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The Oncology Department was established in 1995 to meet the new requirements of oncology, or cancer, such as coordinating all the different departments involved and creating fully interdisciplinary, multidisciplinary teams. Our centre has been used as a model around Europe.
Since its creation, our Department has enjoyed significant quantitative and qualitative growth in the areas of patient care, teaching and research. Cancer is an increasingly common illness; we offer high-quality care linked to clinical and translational research, applying the knowledge of basic research to the prevention and treatment of clinical cases. This means we can see patients from outside our catchment area who can participate in clinical trials. We are a reference centre in all areas of clinical oncology.
These diseases are complex to diagnose and treat, making a multidisciplinary approach essential. That is why our Department works to incorporate a range of professional techniques and contributions to tackle all aspects of care and integrate them into the care process. This means we can improve the care process and ensure quality. Examples of this are our genetic counselling and high-risk illness prevention clinics.
In accordance with the analysis and forecasts included in the latest version of the Catalan Health Plan and the Oncology Master Plan, we must bring forward priority actions in the field of oncological disease in Catalonia. Vall d'Hebron University Hospital is especially equipped to offer a comprehensive Oncology Care Plan, with different services all working in coordination. This is possible thanks to our specialised departments such as Medical Oncology, Radiation Oncology, Clinical Haematology, surgical specialties, medical specialties, Pathological Anatomy, Image Diagnostics and Primary Care. Our professional expertise and ability to work in collaboration are the key to fulfilling this mission.
This is why care for people suffering from oncology is structured into processes in place for all operations, with appropriate timing based on a holistic vision of the care process. At our Department, we incorporate everything these patients need in terms of prevention, diagnosis, treatment and follow-up.
We base this oncological care on three central pillars: our staff, equipment and clinical research. On the one hand, we guarantee the excellence of our staff through internal training programmes in the field of hospital care, as well as establishing collaboration and training exchanges with other renowned, prestigious centres. On the other hand, we offer the latest equipment and carry out clinical, translational and basic research.
We are working to incorporate primary care into the network of oncology treatment at the Hospital, as we believe holistic care in oncology requires incorporation and coordination of all the different healthcare areas involved in treating patients.
As mentioned previously, research is one of the key pillars of our Department, and we are present at the most prestigious international forums where future research and oncological care are discussed. We participate in Cancer Core Europe, the largest cancer platform in Europe, where our Department is one of just seven European departments present.
We have a biomedical research centre made up of scientists and doctors who work together to link basic science with clinical research: the Vall d'Hebron Institute of Oncology (VHIO). Our main purpose is to promote and develop excellence in research into oncological diseases.
The VHIO also works to increase our contribution to the development of new therapies that improve the treatment of cancer. Its goals also include modelling scientific practices in the clinic for the benefit of oncology patients, excellence in scientific research in the fields of basic, translational and clinical research, and scientific cooperation between national and international cancer research institutions. By promoting all activities related to cancer research, we contribute to improving the quality of life of our patients.
Biomedical research in gynaecology
Gynaecological Neoplasia
Biomedical research in urology
Thoracic Tumours and Head and Neck Cancer
Translational molecular pathology
Oncology Data Science
Growth Factors
Radiation Oncology
Experimental Therapy
Proteomics
Tumour Therapy Modelling in Rats
Molecular Oncology
Breast Cancer and Melanoma
Biomedical research in cancer stem cells
Early Clinical Development of Drugs
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.